Medicare GLP-1 Bridge: Program Officially Launches on July 1, 2026, Unlocking Access for Millions of Seniors

Medicare GLP-1 Bridge: Program Officially Launches on July 1, 2026, Unlocking Access for Millions of Seniors

The Centers for Medicare & Medicaid Services (CMS) officially launched the Medicare GLP-1 Bridge Program on July 1, 2026. This temporary 18-month demonstration program, running through December 31, 2027, marks the first time Medicare has ever covered obesity-specific medications.¹ Under the program, eligible beneficiaries can access select blockbusters—Novo Nordisk’s Wegovy (injection and tablet) and Eli Lilly’s Zepbound (KwikPen) and Foundayo—for a flat copay of $50 per month, a massive reduction from standard cashpay costs.

Operational Mechanics and the Role of Humana

Unlike traditional Medicare Part D coverage, the Bridge program is funded directly by taxpayer dollars rather than private insurers.² To bypass the statutory ban on Medicare coverage of weight-loss drugs, CMS has designed a unique administrative framework:

• Central Administrator: CMS has contracted with Humana to process all prior authorizations and approvals.
• Prior Authorization Process: Healthcare providers must submit prior authorization requests directly to Humana certifying that the patient meets clinical requirements. CMS expects these requests to be processed within 72 hours of receipt.
• Eligibility Criteria: Beneficiaries must have a body mass index (BMI) of 35 or higher, or a BMI of 30+ with at least one weight-related comorbidity (e.g., prediabetes, uncontrolled hypertension, or cardiovascular disease). Patients already receiving GLP-1s through Part D for FDA-approved indications (such as Type 2 diabetes or sleep apnea) are not eligible for the Bridge program.
• Cost Structure: The flat $50 monthly copay applies to all doses and will not count toward a patient's Part D deductible or the $2,100 annual out-of-pocket cap.

Market and Clinical Implications

For drugmakers Eli Lilly and Novo Nordisk, the program unlocks a massive new patient pool. An estimated 15 to 20 million older adults in Medicare qualify for weight-loss therapeutics, and CMS expects "several million" to seek access under the Bridge program. This creates a "jump ball" for market share, particularly for the oral formulations—Novo's oral Wegovy tablet and Lilly's newly approved Foundayo pill—which are highly favored by seniors.

However, clinical experts and health policy analysts warn of significant near-term friction:

• Systemic Strain: Clinics and pharmacies are bracing for an immediate influx of pent-up demand, which may cause delays in booking appointments or acquiring the medications.
• The "Cliff" of 2027: Because obesity drugs are lifelong therapies, the temporary nature of the Bridge program creates severe anxiety. CMS's proposed follow-on program, Balance, is designed to shift coverage to private Part D insurers in 2028, but major payers like CVS and UnitedHealthcare have already declined to participate voluntarily due to cost concerns.

"Starting Wednesday, eligible beneficiaries can get GLP-1s to treat obesity for a copay of just $50 per month. It’s a watershed move that could unlock a vast new patient population for Novo Nordisk and Eli Lilly and dramatically expand access to medications that were previously out of reach for many people ages 65 and above."

"There’s also a larger question hanging over the Medicare breakthrough: Unless the Trump administration extends or replaces the demonstration program, obesity drug coverage is scheduled to expire at the end of 2027. Covering the drugs permanently would require a change in federal law or at least agreement among private health insurers to provide the medications in Part D plans."